Evidence map›Paper›PMID 42780989›Full record

ArticleInternational cancer conference journal2026

Myeloid neoplasms post cytotoxic therapy (MN-pCT) following neoadjuvant chemotherapy in a patient with

Hisako Yano, Kanae Taruno, Nana Arai, Sae You, Mieko Takeuchi, Hitomi Sakai, Junji Tsurutani, Norimichi Hattori

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International cancer conference journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hisako YanoDivision of Breast Surgical Oncology, Department of Surgery, School of Medicine, Showa Medical University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555 Japan.
Kanae TarunoDivision of Breast Surgical Oncology, Department of Surgery, School of Medicine, Showa Medical University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555 Japan.ORCID 0000-0002-7754-1548
Nana AraiDivision of Hematology, Department of Medicine, School of Medicine, Showa Medical University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555 Japan.
Sae YouDivision of Breast Surgical Oncology, Department of Surgery, School of Medicine, Showa Medical University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555 Japan.
Mieko TakeuchiDivision of Breast Surgical Oncology, Department of Surgery, School of Medicine, Showa Medical University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555 Japan.
Hitomi SakaiAdvanced Cancer Translational Research Institute, Showa Medical University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555 Japan.
Junji TsurutaniAdvanced Cancer Translational Research Institute, Showa Medical University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555 Japan.
Norimichi HattoriDivision of Hematology, Department of Medicine, School of Medicine, Showa Medical University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555 Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myeloid neoplasms post cytotoxic therapy (MN-pCT), a rare but severe complication of cytotoxic chemotherapy, is particularly associated with alkylating agents and topoisomerase II inhibitors. Although the risk of MN-pCT is well-recognized in

Indexed as

BRCA1 pathogenic variant-associated triple-negative breast cancerCase reportMyeloid neoplasms post cytotoxic therapy (MN-pCT)Neoadjuvant chemotherapy

Identifiers

PMID42780989
PMCPMC13597969

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.